Eyenovia, Inc. (EYEN)
NASDAQ: EYEN · Real-Time Price · USD
0.487
-0.014 (-2.72%)
At close: Nov 7, 2024, 4:00 PM
0.490
+0.003 (0.70%)
After-hours: Nov 7, 2024, 6:56 PM EST
Eyenovia Employees
Eyenovia had 57 employees as of December 31, 2023. The number of employees increased by 16 or 39.02% compared to the previous year.
Employees
57
Change (1Y)
16
Growth (1Y)
39.02%
Revenue / Employee
$551
Profits / Employee
-$654,064
Market Cap
42.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Inotiv | 2,055 |
Allurion Technologies | 504 |
HOOKIPA Pharma | 179 |
Accelerate Diagnostics | 134 |
iCAD, Inc. | 69 |
Unicycive Therapeutics | 14 |
VYNE Therapeutics | 10 |
Incannex Healthcare | 9 |
EYEN News
- 12 hours ago - Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th - GlobeNewsWire
- 22 days ago - Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo - GlobeNewsWire
- 5 weeks ago - Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device - GlobeNewsWire
- 5 weeks ago - Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering - GlobeNewsWire
- 6 weeks ago - Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery - GlobeNewsWire
- 2 months ago - Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization - PRNewsWire
- 2 months ago - Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. - GlobeNewsWire
- 2 months ago - Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer - GlobeNewsWire